Home › Upcoming votes › Endovia Health Sciences, Inc.
The deadline as the proxy statement states it: “voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on December 6, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in Endovia Health Sciences, Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | APPROVE THE ISSUANCE OF COMMON STOCK UNDER THE SERIES D CONVERTIBLE PREFERRED STOCK AND CONVERTIBLE PROMISSORY NOTE (THE "ISSUANCE PROPOSAL") | Board | For | — |
| 2 | APPROVE THE ISSUANCE OF SHARES OF THE COMPANY'S COMMON STOCK PURSUANT TO THE ELOC AGREEMENT | Board | For | — |
| 3 | TO APPROVE AN AMENDMENT TO OUR CHARTER TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK TO 800,000,000 | Board | For | — |
| 4 | Approval of the Reverse Split | Board | For | — |
| 5 | ADJOURNMENT OF THE SPECIAL MEETING Adjournment |
Board | For | — |
From Endovia Health Sciences, Inc.’s Form 8-K, filed November 6, 2025, for the meeting held October 31, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Robert Nistico | — | — |
| Elect Director: Justin Yorke | — | — |
| Elect Director: Thomas Fore | — | — |
| Elect Director: Frederick William ("Bill") Caple | — | — |
| Proposal 2. The Company's stockholders voted to ratify the appointment of Rose, Snyder & Jacobs LLP as the Company's independent registered | 95% | Approved |
| 3. The Company's stockholders voted to approval the issuance of common stock in excess of 379,785 shares pursuant to outstanding convertible | 96% | — |
| Proposal 4. The Company's stockholders voted to approve the issuance of shares of the Company's common stock pursuant to the ELOC Agreement | 97% | Approved |
| Proposal 5. The Company's stockholders voted to approve the 2025 Equity Incentive Plan. | 93% | Approved |
| 6. The Company's stockholders voted not to approve the possible increase of the Company's common stock to 400,000,000 shares | 88% | — |
| Proposal 7. The Company's stockholders voted to approve an adjournment of the Annual Meeting. | 89% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.